MAPKs are widely regarded as important therapeutic targets for inflammatory diseases, including osteoporosis (Ullah et al., 2022; Gao et al., 2023), but the involvement of DUSP4 in osteoclast MAPK regulation has not been previously reported. Here, DUSP4 is linked to osteoporosis.